TY - JOUR AU - S., AKILA AU - S., MALAR VIZHI AU - P., VIJAYALAKSHMI AU - A., CLARA MARY AU - M., RAJALAKSHMI PY - 2021/07/15 Y2 - 2024/03/28 TI - PREDICTION OF ANTI-ALZHEIMER’S ACTIVITY OF FLAVONOIDS TARGETING CD33 THROUGH IN-SILICO APPROACH JF - International Journal of Current Pharmaceutical Research JA - Int J Curr Pharm Sci VL - 13 IS - 4 SE - Original Article(s) DO - 10.22159/ijcpr.2021v13i4.42746 UR - https://journals.innovareacademics.in/index.php/ijcpr/article/view/42746 SP - 64-66 AB - <p><strong>Objective: </strong>Alzheimer's disease (AD) is a progressive, fatal brain disorder that would be putting a growing strain on health and social care systems. Present anti-AD agents are limited in their application due to their adverse effects, toxicity, and limited targets in AD pathology. As a result, it is important to develop an AD-fighting compound. Some flavonoids (such as kaempferol, myricetin, quercetin, and syringetin) have been shown to be effective in the treatment of Alzheimer's disease.</p><p><strong>Methods: </strong>We chose 284 flavonoids from the NPACT database for molecular docking studies in order to examine their binding interactions with the Alzheimer target protein CD33.</p><p><strong>Results: </strong>These compounds exhibited significant docking interactions with a variety of targets implicated in the pathogenesis of AD. We chose the top three compounds (Rutin, Morin, and,4,4'-Trihydroxydihydrochalcone) based on the scoring parameter.</p><p><strong>Conclusion: </strong>These compounds exhibited favorable pharmacokinetic properties, indicating that they could be attractive drug candidates for the treatment of Alzheimer's disease.</p> ER -